FDA Classifies Esophagus Deflector for Cardiac Zaps
Published Date: 9/10/2026
Rule
Summary
The FDA is officially classifying a new device that protects the esophagus during heart procedures as a Class II device, meaning it’s safe and effective with some special rules. This change helps patients get access to this cool innovation faster by cutting down on red tape. The new classification took effect on September 10, 2026, but has been in place since September 6, 2023, making it easier and potentially cheaper for makers to bring this device to market.
Analyzed Economic Effects
4 provisions identified: 2 benefits, 2 costs, 0 mixed.
Device Reclassified to Class II
If you make or sell this esophageal deviation device, the FDA has classified it as Class II (special controls). The order adding 21 CFR 870.5710 is effective September 10, 2026 and the classification was applicable on September 6, 2023, which reduces regulatory burdens compared with automatic Class III assignment.
510(k) Premarket Submission Required
If you plan to market this mechanical esophageal deviation device, the device is subject to premarket notification under section 510(k) of the FD&C Act. FDA states it has not determined 510(m) exemption for this device type, so sponsors must submit a 510(k) to reasonably assure safety and effectiveness.
Required Special Controls and Testing
Manufacturers must meet the special controls in 21 CFR 870.5710, including clinical performance testing (evaluation of reduced esophageal injury and any esophageal or oral injury), animal performance testing (capability to deviate the esophagus including trailing edge and evaluate injury), non-clinical mechanical integrity and compatibility testing, sterility demonstration, biocompatibility, shelf-life data, and specific labeling (summary of clinical testing and shelf life).
Patient Access to New Esophageal Protection
The FDA says this Class II action will enhance patients' access to this esophageal protection device during cardiac ablation procedures by reducing regulatory burdens and making it easier and potentially cheaper for makers to bring the device to market. The order notes the classification was applicable on September 6, 2023 and finalized September 10, 2026.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20727, Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorganism(s) Causing Sexually Transmitted Infections Using Home-Collected Specimens
The FDA is officially classifying home test kits that detect non-viral germs causing sexually transmitted infections as Class II devices, meaning they have special safety rules but fewer hurdles than the strictest category. This change, effective October 9, 2026, helps make these tests safer and easier to get, benefiting patients and innovators alike. If you make or use these home test kits, this update means better access and clear safety standards without extra costs or delays.
Previous / Next Documents
Previous: 2026-18432, Medical Devices; Cardiovascular Devices; Classification of the Temperature Regulation Device for Esophageal Protection During Cardiac Ablation Procedures
The Food and Drug Administration (FDA) is classifying the temperature regulation device for esophageal protection during cardiac ablation procedures into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the temperature regulation device for esophageal protection during cardiac ablation procedures. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of the safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.
Next: 2026-18437, Amendment of Class D and Class E Airspace and Establishment of Class E Airspace; Clovis, NM, and Portales, NM
This action amends the Class D and Class E airspace at Clovis, NM, and establishes Class E airspace at Clovis, NM, and Portales, NM. This action is the result of a biennial airspace review conducted for Cannon AFB (Air Force Base), Clovis, NM, and airspace reviews conducted at Clovis Regional Airport, Clovis, NM, and Portales Municipal Airport, Portales, NM, due to updated instrument procedures. The name and geographic coordinates for the Cannon TACAN are also being updated to coincide with the FAA's aeronautical database. This action brings the airspace into compliance with FAA orders and supports instrument flight rule (IFR) procedures and operations.